{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:14:47Z","timestamp":1778793287382,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["221295\/Z\/20\/Z"],"award-info":[{"award-number":["221295\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RG\/16\/10\/32375"],"award-info":[{"award-number":["RG\/16\/10\/32375"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/19\/34\/34354"],"award-info":[{"award-number":["FS\/19\/34\/34354"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000589","name":"Chief Scientist Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000589","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013915","name":"EPSRC Centre for Doctoral Training in Smart Medical Imaging","doi-asserted-by":"publisher","award":["EP\/M506539\/1"],"award-info":[{"award-number":["EP\/M506539\/1"]}],"id":[{"id":"10.13039\/501100013915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003302","name":"American Association for the Surgery of Trauma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007431","name":"Neurosciences Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014989","name":"The Chan Zuckerberg Initiative","doi-asserted-by":"publisher","award":["DAF2021-225273"],"award-info":[{"award-number":["DAF2021-225273"]}],"id":[{"id":"10.13039\/100014989","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000923","name":"Silicon Valley Community Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020414","name":"Neurosciences Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bmc.2024.118057","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T21:53:36Z","timestamp":1736027616000},"page":"118057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Assessment of a 6-arylaminobenzamide lead derivative as a potential core scaffold for S1P5 positron emission tomography radiotracer development"],"prefix":"10.1016","volume":"119","author":[{"given":"Robert C.","family":"Shaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timaeus E.F.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"McErlain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos J.","family":"Alcaide-Corral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam D.","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Soloviev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Y.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana A.S.","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.118057_b0005","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.bmc.2024.118057_b0010","unstructured":"Published CU. Ocrelizumab for treating primary progressive multiple sclerosis. 2018;(June):1\u201319. Available from: https:\/\/www.nice.org.uk\/guidance\/TA585."},{"key":"10.1016\/j.bmc.2024.118057_b0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nrneurol.2015.14","article-title":"Multiple sclerosis - A quiet revolution","volume":"11","author":"Ransohoff","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.bmc.2024.118057_b0020","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1074\/jbc.M003964200","article-title":"Nrg-1 belongs to the endothelial differentiation gene family of G protein-coupled sphingosine-1-phosphate receptors","volume":"276","author":"Malek","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2024.118057_b0025","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1749-6632.2000.tb06544.x","article-title":"EDG receptors as a therapeutic target in the nervous system","volume":"905","author":"Beer","year":"2000","journal-title":"Ann N Y Acad Sci [internet]."},{"key":"10.1016\/j.bmc.2024.118057_b0030","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1124\/pr.110.003111","article-title":"International union of basic and clinical pharmacology. LXXVIII Lysophospholipid","volume":"62","author":"Chun","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bmc.2024.118057_b0035","doi-asserted-by":"crossref","first-page":"14053","DOI":"10.1021\/bi011606i","article-title":"Characterization of the human and mouse sphingosine 1-phosphate receptor, S1P5 (Edg-8): structure\u2013activity relationship of sphingosine1-phosphate receptors","volume":"40","author":"Im","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2024.118057_b0040","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0306-4522(02)00791-1","article-title":"Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS","volume":"116","author":"Terai","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.bmc.2024.118057_b0045","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1523\/JNEUROSCI.4645-04.2005","article-title":"Edg8\/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival","volume":"25","author":"Jaillard","year":"2005","journal-title":"J Neurosci [Internet]."},{"key":"10.1016\/j.bmc.2024.118057_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphy.2013.00001","article-title":"Grand challenges in biomedical physics","volume":"1","author":"Townsend","year":"2013","journal-title":"Front Phys"},{"key":"10.1016\/j.bmc.2024.118057_b0055","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/cmdc.201000253","article-title":"Design and synthesis of selective and potent orally active S1P5 agonists","volume":"5","author":"Mattes","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2024.118057_b0060","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1476-5381.2009.00604.x","article-title":"Ligand binding assays at equilibrium: Validation and interpretation","volume":"161","author":"Hulme","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2024.118057_b0065","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.2174\/13852728113179990104","article-title":"Automated C-11 methyl iodide\/triflate production: current state of the art","volume":"17","author":"Mock","year":"2013","journal-title":"Curr Org Chem"},{"key":"10.1016\/j.bmc.2024.118057_b0070","unstructured":"Tavares A, Becker G, Barret O, et al.. Initial evaluation of [18F]F13714, a novel 5-HT1A receptor agonist in non-human primates. In: Annual Congress of the European Association of Nuclear Medicine [Internet]. 2013. Available from: https:\/\/hal.science\/hal-00948404."},{"key":"10.1016\/j.bmc.2024.118057_b0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.bmc.2024.118057_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2020.00871","article-title":"Rapidly (and successfully) translating novel brain radiotracers from animal research into clinical use","volume":"14","author":"Shaw","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1016\/j.bmc.2024.118057_b0085","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.tips.2009.05.005","article-title":"PET radiotracers: crossing the blood-brain barrier and surviving metabolism","volume":"30","author":"Pike","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bmc.2024.118057_b0090","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/026988119300700202","article-title":"Positron-emitting radioligands for studies in vivo - Probes for human","volume":"7","author":"Pike","year":"1993","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.bmc.2024.118057_b0095","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.mibio.2003.09.009","article-title":"Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography","volume":"5","author":"Laruelle","year":"2003","journal-title":"Mol Imag Biol"},{"key":"10.1016\/j.bmc.2024.118057_b0100","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/cmdc.201000477","article-title":"BZM055, an iodinated radiotracer candidate for PET and SPECT imaging of myelin and FTY720 brain distribution","volume":"6","author":"Briard","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2024.118057_b0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1054\/plef.2000.0191","article-title":"Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update","volume":"63","author":"Bennett","year":"2000","journal-title":"Prostaglandins Leukot Essent Fat Acids"},{"key":"10.1016\/j.bmc.2024.118057_b0110","doi-asserted-by":"crossref","unstructured":"Herman JP, Watson SJ. The rat brain in stereotaxic coordinates (2nd edn). Vol. 10, Trends in Neurosciences. 1987. 439 p.","DOI":"10.1016\/0166-2236(87)90017-8"},{"key":"10.1016\/j.bmc.2024.118057_b0115","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0006-3495(99)77181-X","article-title":"Three-dimensional imaging of nerve tissue by X-ray phase-contrast microtomography","volume":"76","author":"Beckmann","year":"1999","journal-title":"Biophys J"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624004711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624004711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:51:09Z","timestamp":1778791869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089624004711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":23,"alternative-id":["S0968089624004711"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.118057","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of a 6-arylaminobenzamide lead derivative as a potential core scaffold for S1P5 positron emission tomography radiotracer development","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.118057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"118057"}}